Détail du document
Identifiant

doi:10.1186/s40694-023-00150-5...

Auteur
Kanlayavattanakul, Mayuree Lourith, Nattaya
Langue
en
Editeur

BioMed Central

Catégorie

Mycology

Année

2023

Date de référencement

08/03/2023

Mots clés
... pharmaceutical product polysaccharide topical product skin care developed safe cordyceps militaris extract polysaccharides
Métrique

Résumé

Background Topical product derived from the fungus Cordyceps militaris was explored as a feasible method for an industrial practice.

Results The mycelium residue of C. militaris that was industrial biotechnological produced was extracted with water at different time conditions under ambient temperature, filtered and lyophilized.

The extracts were all light to dark brown powder.

The 24 h extraction was significantly (p < 0.01) highest in an extractive yield and total polysaccharides content (TPC) (43.33 ± 0.99% and 144.02 ± 2.06 mg glucose/g crude extract).

This extract was proved to be stable following an accelerated stability test with the insignificant (p > 0.05) reduction of TPC (4.95 ± 2.23%).

Topical product containing the extract were developed.

Skin care preparation containing 0.2% extract was exhibited as the appropriated amount giving the stable cream.

The developed C. militaris polysaccharide cream was confirmed safe and gained more than 70% of the overall preferences examined in 20 female volunteers.

Conclusions Cordyceps militaris mycelium residue is a beneficial source for pharmaceutical products.

The C. militaris polysaccharides extract was prepared and qualified in terms of active content and stability.

The extract was shown to be compatible with the available cosmetic ingredients.

The safe and preferred C. militaris polysaccharides skin care cosmetics was developed.

Accordingly, C. militaris polysaccharides skin care cosmetics that meets all the quality characters which are stable, safe, usable and efficient.

Kanlayavattanakul, Mayuree,Lourith, Nattaya, 2023, Cordyceps militaris polysaccharides: preparation and topical product application, BioMed Central

Document

Ouvrir

Partager

Source

Articles recommandés par ES/IODE IA

MELAS: Phenotype Classification into Classic-versus-Atypical Presentations
presentations mitochondrial strokelike patients variability phenotype clinical melas
Protocol for the promoting resilience in stress management (PRISM) intervention: a multi-site randomized controlled trial for adolescents and young adults with advanced cancer
cancer quality of life anxiety depression hope coping skills communication intervention randomized ayas outcomes resilience care trial cancer prism-ac advanced